Ligand-independent actions of estrogen receptors (ERs) have also been described, particularly in the uterus, where ER can be activated by growth factor pathways (e.g., IGF-1), leading to receptor recruitment to chromatin in the absence of estrogen binding (Meyer et al., 2011
Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, et al
Food and Drug Administration (FDA) does not approve supplements for safety and effectiveness, so we recommend choosing brands that have been tested by a credible third-party for purity, potency and safety
Indian journal of endocrinology and metabolism
Do not repurpose research materials for any non-laboratory application